Article
Endocrinology & Metabolism
Giuseppe Giuffrida, Valeria D'Argenio, Francesco Ferrau, Vito Alessandro Lasorsa, Francesca Polito, Federica Aliquo, Marta Ragonese, Oana Ruxandra Cotta, Ylenia Alessi, Rosaria Oteri, Federica Di Maggio, Alessio Asmundo, Petronilla Daniela Romeo, Federica Spagnolo, Lucio Pastore, Filippo Flavio Angileri, Mario Capasso, Salvatore Cannavo, M'Hammed Aguennouz
Summary: The study found that there are complex epigenetic modifications, mainly methylation and miRNA activity, in pituitary adenomas. Nonfunctioning tumors (NFPAs) showed higher methylation levels compared to GH-omas, with 178 differentially methylated regions (DMRs) mainly located in noncoding and intronic sequences. Additionally, the study identified three hypermethylated genes involved in tumorigenesis processes.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Endocrinology & Metabolism
Tamara Kolitz, Yona Greenman
Summary: Non-functioning pituitary adenomas (NFPAs) are silent tumors of different pituitary lineages that are difficult to detect early and present as invasive macroscopic tumors with mass effect symptoms. They often cannot be completely surgically removed and may have subsequent remnant progression. When NFPAs show resistance to optimal standard therapies including surgery, radiotherapy, and medical treatment, they are classified as refractory.
Article
Neurosciences
Eric J. Lehrer, Roman O. Kowalchuk, Daniel M. Trifiletti, Jason P. Sheehan
Summary: Pituitary adenomas are common benign brain tumors, comprising 10%-20% of all central nervous system neoplasms. Stereotactic radiosurgery (SRS) has emerged as an effective treatment option for these tumors, with high tumor control rates. However, potential side effects such as endocrine dysfunction and visual deficits need to be considered. Hypofractionated SRS, delivered in multiple fractions, is an alternative treatment option for patients who are not suitable for single fraction SRS.
Article
Endocrinology & Metabolism
Kunzhe Lin, Jianping Zhang, Yinghong Lin, Zhijie Pei, Shousen Wang
Summary: This study investigated the metabolic differences between invasive and non-invasive NFPAs and found distinct metabolite profiles. It also confirmed the high expression of the M2 macrophage marker in invasive NFPAs.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Clinical Neurology
Kihwan Hwang, Yong Hwy Kim, Jung Hee Kim, Jung Hyun Lee, Hee Kyung Yang, Jeong-Min Hwang, Chae-Yong Kim, Jung Ho Han
Summary: The study on the natural history of asymptomatic nonfunctioning pituitary adenomas (NFPAs) with optic nerve compression showed that close follow-up and timely surgical intervention can effectively prevent visual and endocrine issues for cases with optic nerve compression, and conservative management is also acceptable for these tumors. Careful follow-up is necessary for tumors with cavernous sinus invasion.
JOURNAL OF NEUROSURGERY
(2021)
Article
Endocrinology & Metabolism
Nasrin Al-Shamkhi, Katarina Berinder, Henrik Borg, Pia Burman, Per Dahlqvist, Charlotte Hoybye, Daniel S. Olsson, Oskar Ragnarsson, Bertil Ekman, Britt Eden Engstrom
Summary: Objective data on pituitary function before and after transsphenoidal surgery in nonfunctioning pituitary adenomas were inconsistent. This study found that adrenocorticotrophic hormone deficiency increased significantly at 1 year postoperatively, while other axis function changes were not significant. Therefore, continuous individual evaluations are needed during longer follow-up of patients operated for NFPA.
EUROPEAN JOURNAL OF ENDOCRINOLOGY
(2023)
Review
Biochemical Research Methods
Ruby C. Y. Lin, Jessica C. Sacher, Pieter-Jan Ceyssens, Jan Zheng, Ali Khalid, Jonathan R. Iredell
Summary: After a century of use in human infection, there is a clear need to improve the reproducibility, safety, and speed of providing suitable phages. Building a national consortium and sustainable phage biobank could serve as a model for phage therapy initiatives.
CURRENT OPINION IN BIOTECHNOLOGY
(2021)
Article
Clinical Neurology
Georgios Mantziaris, Stylianos Pikis, Tomas Chytka, Roman Liscak, Kimball Sheehan, Darrah Sheehan, Selcuk Peker, Yavuz Samanci, Shray K. Bindal, Ajay Niranjan, L. Dade Lunsford, Rupinder Kaur, Renu Madan, Manjul Tripathi, Dhiraj J. Pangal, Ben A. Strickland, Gabriel Zada, Anne-Marie Langlois, David Mathieu, Ronald E. Warnick, Samir Patel, Zayda Minier, Herwin Speckter, Zhiyuan Xu, Rithika Kormath Anand, Jason P. Sheehan
Summary: This study analyzed 375 patients with residual nonfunctioning pituitary adenomas (NFPAs) who were treated with stereotactic radiosurgery (SRS) and compared the outcomes between early treatment and treatment at progression. The results showed that there was no significant difference in tumor control and preservation of hormonal/visual function between SRS at residual NFPA progression and adjuvant SRS. Deferring radiosurgical management to the time of radiological progression could prolong the onset of radiosurgically induced pituitary dysfunction.
JOURNAL OF NEUROSURGERY
(2023)
Article
Endocrinology & Metabolism
Tobias Hallen, Gudmundur Johannsson, Rahil Dahlen, Camilla A. M. Glad, Charlotte Orndal, Angelica Engvall, Helena Caren, Thomas Skoglund, Daniel S. Olsson
Summary: This study explored DNA methylation patterns associated with tumor progression in patients with nonfunctioning pituitary adenomas (NFPAs). The results showed that some methylation sites were associated with tumor progression and could potentially serve as biomarkers for early identification of tumor progression.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2022)
Article
Endocrinology & Metabolism
Yi Fang, He Wang, Ming Feng, Wentai Zhang, Lei Cao, Chenyu Ding, Hongjie Chen, Liangfeng Wei, Shuwen Mu, Zhijie Pei, Jun Li, Heng Zhang, Renzhi Wang, Shousen Wang
Summary: Accurate predictive models for hormonal prognosis in NFPA were lacking. Machine learning models were developed to assess pituitary hormonal outcomes post-surgery, showing significant changes in hormone levels and the effectiveness of ML in predicting outcomes.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Article
Genetics & Heredity
Sen Cheng, Jing Guo, Dawei Wang, Qiuyue Fang, Yulou Liu, Weiyan Xie, Yazhuo Zhang, Chuzhong Li
Summary: By constructing an effective lncRNA signature, we successfully predicted the risk of recurrence in nonfunctioning pituitary adenomas after surgery, providing potential therapeutic targets for patients.
FRONTIERS IN GENETICS
(2021)
Article
Clinical Neurology
Satoru Oshino, Youichi Saitoh, Manabu Kinoshita, Kosuke Mukai, Michio Otsuki, Haruhiko Kishima
Summary: The study revealed that in NFPAs causing sAI, factors such as Knosp grade and sex are more influential. sAI patients are usually male, and tumors that extend bilaterally with lower Knosp grades are common.
WORLD NEUROSURGERY
(2021)
Review
Endocrinology & Metabolism
Eliza B. Geer
Summary: Refractory pituitary adenomas are those that have progressed following standard of care treatments. Medical therapy options for these challenging tumors are limited. There are currently no approved non-endocrine medical therapies for refractory pituitary tumors, highlighting the urgent need for identifying effective treatments and conducting multi-center clinical trials.
Review
Oncology
Covadonga Marti, Jose Ignacio Sanchez-Mendez
Summary: Treatment of breast cancer has evolved towards individualized management, with hormone therapy playing a key role. Neoadjuvant endocrine therapy has become an effective approach for many hormone receptor-positive breast cancers.
Article
Oncology
Daniela Modena, Maria Luisa Moras, Giovanni Sandrone, Andrea Stevenazzi, Barbara Vergani, Pooja Dasgupta, Andrea Kliever, Sebastian Gulde, Alessandro Marangelo, Mathias Schillmaier, Raul M. Luque, Stephen Baeuerle, Natalia S. Pellegata, Stefan Schulz, Christian Steinkuehler
Summary: Therapy for nonfunctioning pituitary adenomas (NFPAs) is an unmet medical need. We discovered that ITF2984, a molecule originally developed as a pan-SSTR agonist, is a full agonist of SSTR3 and showed significant antitumor activity in an in vivo model. ITF2984 may provide a new therapeutic option for NFPA patients.
